DaVita Gains 1.3% to $179.25 with Q3 EPS Projected Up 50.6% YoY
Question
DaVita Gains 1.3% to $179.25 with Q3 EPS Projected Up 50.6% YoY
Direct answer
Operating leverage from specialized outpatient dialysis center utilization drives DaVita's projected 50.60% EPS expansion at a 12.15 forward earnings multiple. — bullish pressure on DVA via outpatient dialysis treatment volume growth and cost containment.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-10
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “DaVita Gains 1.3% to $179.25 with Q3 EPS Projected Up 50.6% YoY”, revision 1, evidence through 2026-10-10. https://marketontology.com/catalysts/2026-10-10/davita-gains-1-3-to-179-25-with-q3-eps-projected-up-50-6-yoy-8987d4
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| DVA | ▲Bull | 1–4 weeks | outpatient dialysis treatment volume growth and cost containment | 59 |
DaVita Gains 1.3% to $179.25 with Q3 EPS Projected Up 50.6% YoY
Operating leverage from specialized outpatient dialysis center utilization drives DaVita's projected 50.60% EPS expansion at a 12.15 forward earnings multiple. — bullish pressure on DVA via outpatient dialysis treatment volume growth and cost containment.
1.26% gain to $179.25 on consensus 50.60% quarterly EPS expansion projection.
- Source1.26% gain to $179.25 on consensus 50.60% quarterly EPS expansion projection.
- TransmissionOperating leverage from specialized outpatient dialysis center utilization drives DaVita's projected 50.60% EPS expansion at a 12.15 forward earnings multiple.
- SummaryDaVita advanced 1.26% to $179.25, outperforming the benchmark index. Upcoming quarterly EPS is forecasted to expand 50.60% year-over-year. Shares trade at a forward P/E of 12.15 against full-year earnings growth projections of 35.16%.
- DVADirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- Sector rotation or peer guidance may override single-name reaction
- DVA closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- DVA price vs. pre-event level
- DVA volume vs. 20-day average
- Sector ETF read-through
- Options implied volatility crush
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- Why DaVita HealthCare (DVA) Outpaced the Stock Market Today · news · 2026-10-09
Related catalysts
- 2026-10-11DaVita Projects 50.6% Quarterly EPS Growth at 12.15x Forward Earnings MultipleDVA
- 2026-10-11DaVita Outperforms S&P 500 on Projected 50.6% Dialysis EPS ExpansionDVA
- 2026-10-11DaVita Outperforms S&P 500 on Projected 50.6% Dialysis EPS ExpansionDVA XLV+3.45%
- 2026-10-11DaVita Projects 50.6% Quarterly EPS Growth at 12.15x Forward Earnings MultipleDVA
- 2026-10-10DaVita Outpaces S&P 500 on Forecast 50.6 Percent Quarterly EPS GrowthDVA SPY-1.97%
- 2026-10-10DaVita Gains as Forward P/E Holds at 12.15x Against 50.6% Projected EPS GrowthDVA
- 2026-10-10DaVita Outpaces S&P 500 on Forecast 50.6 Percent Quarterly EPS GrowthDVA SPY-1.97%
- 2026-10-10DaVita Gains as Forward P/E Holds at 12.15x Against 50.6% Projected EPS GrowthDVA
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.